Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.
AIMS: To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. RESULTS: Participants (mean age 42.8 years, BMI 37.4 kg/m(2), HbA1c 64.3 mmol/mol, 32% male) were followed up for a median of 365 days.
AIMS: To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. RESULTS: Participants (mean age 42.8 years, BMI 37.4 kg/m(2), HbA1c 64.3 mmol/mol, 32% male) were followed up for a median of 365 days.
What the study was
- Study design
- Cohort study
- Category
- Prevention
- Maturity
- Validated
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
Relevant Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk study (near-term clinical implementability) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.